|1.||Ntambi, James M: 13 articles (03/2014 - 07/2002)|
|2.||Miyazaki, Makoto: 6 articles (01/2010 - 07/2002)|
|3.||Flowers, Matthew T: 6 articles (01/2010 - 06/2006)|
|4.||Liu, Xueqing: 4 articles (01/2010 - 06/2006)|
|5.||Chu, Kiki: 4 articles (01/2010 - 09/2006)|
|6.||Sampath, Harini: 4 articles (01/2010 - 12/2005)|
|7.||Polotsky, Vsevolod Y: 3 articles (04/2010 - 06/2007)|
|8.||Wang, Hui: 2 articles (07/2015 - 04/2013)|
|9.||Vessby, Bengt: 2 articles (03/2014 - 07/2007)|
|10.||Igal, R Ariel: 2 articles (09/2012 - 06/2011)|
02/01/2013 - "Expression and/or activity of stearoyl-CoA desaturase-1 (SCD1), a major regulator of lipid metabolism, is increased with obesity and the reduction/ablation of this enzyme is associated with an improved metabolic profile. "
01/24/2013 - "Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome."
01/01/2012 - "Obesity and its metabolic complications are associated with increased expression/activity of stearoyl-CoA desaturase-1 (SCD1), a major regulator of lipid metabolism. "
12/15/2011 - "Stearoyl-CoA desaturase1 (SCD1) whole body deficiency protects mice from diet-induced obesity. "
07/24/2009 - "Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity."
03/01/2011 - "Stearoyl-CoA desaturase-1 is associated with insulin resistance in morbidly obese subjects."
06/01/2006 - "Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance."
06/01/2006 - "Probing the role of stearoyl-CoA desaturase-1 in hepatic insulin resistance."
03/20/2009 - "Mice deficient in the enzyme stearoyl-CoA desaturase-1 (SCD1) are lean and protected from diet-induced obesity and insulin resistance. "
12/01/2005 - "In mice, targeted disruption of the stearoyl-CoA desaturase-1 (SCD1) gene results in the generation of a lean mouse that is resistant to diet-induced obesity and insulin resistance. "
06/23/2015 - "Hepatic SirT1-Dependent Gain of Function of Stearoyl-CoA Desaturase-1 Conveys Dysmetabolic and Tumor Progression Functions."
11/05/2012 - "Progestin treatment induced stearoyl CoA desaturase-1 (SCD-1) enzyme expression and chemical inhibition of SCD-1 diminished lipid droplets and cell viability, suggesting the importance of lipid stores in cancer cell survival. "
12/10/1973 - "Dietary control of stearyl CoA and alkylacylglycerophosphorylethanolamine desaturases in tumor."
07/01/2015 - "Stearoyl-coenzyme A desaturase-1 (SCD1) has an important role in lipid metabolism, and SCD1 inhibitors are potential therapeutic agents for the treatment of metabolic diseases and cancers. "
01/01/2015 - "Stearoyl-CoA desaturase-1 (SCD-1) catalyzes the production of monounsaturated fatty acids that are essential for membrane biogenesis, and is required for cell proliferation in many cancer cell types. "
06/01/2006 - "Previous studies using stearoyl-CoA desaturase-1-deficient (SCD1-deficient) mice have shown that this enzyme plays an important role in many diseases of altered cellular metabolism including obesity, insulin resistance, and dyslipidemia. "
11/07/2008 - "Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase."
03/01/2014 - "Although a clear causal relationship of OSA and dyslipidemia is yet to be demonstrated, there is increasing evidence that chronic intermittent hypoxia, a major component of OSA, is independently associated and possibly the root cause of the dyslipidemia via the generation of stearoyl-coenzyme A desaturase-1 and reactive oxygen species, peroxidation of lipids, and sympathetic system dysfunction. "
11/07/2008 - "We have previously shown that C57BL/6J mice exposed to CIH and a high-cholesterol diet develop dyslipidemia, atherosclerosis of the aorta, and upregulation of a hepatic enzyme of lipoprotein secretion, stearoyl coenzyme A desaturase 1 (SCD-1). "
06/15/2007 - "Compared with mice exposed to intermittent air and a high-cholesterol diet, combined exposure to CIH and a high-cholesterol diet resulted in marked progression of dyslipidemia with further increases in serum total cholesterol and low-density lipoprotein cholesterol (124 +/- 4 vs. 106 +/- 6 mg/dl; p < 0.05), a twofold increase in serum lipid peroxidation, and up-regulation of an important hepatic enzyme of lipoprotein secretion, stearoyl-coenzyme A desaturase-1. "
01/01/2003 - "These analyses indicated that stearoyl-coenzyme A (Delta9) desaturase, a key enzyme involved in the regulation of triglyceride biosynthesis and secretion, is a potential target for nutritional intervention for hyperlipidemia and cardiovascular health. "
01/01/2011 - "One possible mechanism underlying these physiological effects is reduction of hepatic levels of the mRNA for stearoyl-CoA desaturase-1 (SCD1), since repression of this enzyme reduces hyperlipidemia and adiposity. "
06/01/2008 - "Recent studies in humans and animal models have highlighted that modulation of stearoyl-coenzyme A desaturase 1 activity by dietary intervention or genetic manipulation strongly influences several facets of energy metabolism to affect susceptibility to obesity, insulin resistance, diabetes and hyperlipidemia."
04/01/2010 - "Hyperlipidemia of intermittent hypoxia occurs, at least in part, due to activation of the transcription factor sterol regulatory element-binding protein-1 (SREBP-1) and an important downstream enzyme of triglyceride and phospholipid biosynthesis, stearoyl-CoA desaturase-1. "
|1.||Fatty Acid Synthetase Complex (Fatty Acid Synthase)
|3.||Biological Markers (Surrogate Marker)
|5.||Monounsaturated Fatty Acids
|6.||Fatty Acids (Saturated Fatty Acids)
|7.||Linoleic Acid (Linoleate)
|8.||alpha-Linolenic Acid (Linolenic Acid)